Sex-Specific Outcomes After Transcatheter Aortic Valve Replacement: FDA Patient-Level Meta-Analysis of Premarket Clinical Trials
Zusterzeel R, Mishra NK, Beydoun H, Laschinger J, Wu C, Dong LM, Lin JA, Marinac-Dabic D, Strauss DG, Caños DA. Sex-Specific Outcomes After Transcatheter Aortic Valve Replacement: FDA Patient-Level Meta-Analysis of Premarket Clinical Trials. Journal Of Women's Health 2018, 27: 808-814. PMID: 29741978, DOI: 10.1089/jwh.2017.6760.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAortic ValveAortic Valve StenosisClinical Trials as TopicComorbidityFemaleHeart Valve Prosthesis ImplantationHumansMalePostoperative HemorrhageSex FactorsTranscatheter Aortic Valve ReplacementTreatment OutcomeConceptsTranscatheter aortic valve replacementAortic valve replacementClinical trialsPatient-level dataPremarket clinical trialsLower riskMajor bleedingKidney injuryIschemic strokeValve replacementPacemaker implantationMortality riskDichotomous outcomesEfficacy of TAVRInvasive alternative approachPatient-Level MetaLong-term outcomesSex-specific outcomesLower mortality riskRandom-effects modelReintervention riskTAVR armIndividual comorbiditiesPostprocedural complicationsAcute outcomes